August 10, 2017. TWi Pharmaceuticals, Inc. (“TWi”) (Stock Ticker: 4180.TT) today announced that the availability of Guanfacine HCl ER Tablets 1mg, 2mg, 3mg and 4mg in TWi label. TWi Guanfacine HCl ER Tablets were previously marketed by Par Pharmaceutical.

Guanfacine HCl ER Tablets are a central alpha2A-adrenergic receptor agonist indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications.

TWi has successfully launched the product in the US via a well-established sales platform by its fully owned subsidiary, TWi Pharmaceuticals USA, Inc., as of August 1, 2017.

According to IMS Health, US sales of Intuniv® marketed by Shire US Inc. and generic Guanfacine HCl ER Tablets were approximately $93 million for the 12 months ended June 2017.

About TWi Pharmaceuticals, Inc.
TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier generic prescription products ranging from oral controlled release dosage form to novel drug delivery systems including the utilization of nanoparticles, transdermal, and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer unparalleled market opportunities in the United States. For more information on TWi Pharmaceuticals and its fully owned US subsidiary, TWi Pharmaceuticals USA, Inc., please visit www.twipharma.com

Contact :
Angela Luan
Investor Relations
Email: angela.luan@twipharma.com